A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Non-Small Cell Lung Cancer|Ovarian Cancer|Fallopian Tube Cancer|Triple Negative Breast Cancer|Multiple Myeloma|Pancreatic Ductal Adenocarcinoma
Interventions: BIOLOGICAL: CART-TnMUC1|DRUG: Cyclophosphamide|DRUG: Fludarabine
Sponsor: Kite, A Gilead Company